Search
Search Results
##search.searchResults.foundPlural##
-
ULTRASOUND AS FIRST LINE STEP IN ANAEMIA DIAGNOSTICS
1505PDF: 928HTML: 1965 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2351PDF: 1094HTML: 2027Characteristic of study group: 222 -
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1191PDF: 543HTML: 389 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
769PDF: 484HTML: 6284 -
NEW STRATEGIES FOR STEM CELL MOBILIZATION
2544PDF: 920HTML: 2571 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1806PDF: 1339HTML: 637 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4624PDF: 1791HTML: 1242 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
577PDF: 283HTML: 122 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1423PDF: 487HTML: 18625Figure 1: 187Figure 2: 167Figure 3: 185Figure 4: 220Figure 5: 198 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4064PDF: 1100HTML: 3899Untitled: 189Cneo. Fig.1: 127Untitled: 122Untitled: 147Untitled: 156 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2334PDF: 857HTML: 1701Figure 1: 228Table 1: 239 -
Aberrant acquisition of T-cell associated markers in plasma cell neoplasms: An aggressive disease with extramedullary involvement and very short survival Aberrant T markers on malignant plasma cells
2086PDF: 451HTML: 233 -
SOLITARY PLASMACYTOMA
4199PDF: 2246HTML: 1405fIGURES 1,2: 254 -
IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA
2641PDF: 1228HTML: 163 -
Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study Ceftolozane-Tazobatam for febrile neutropenia
7969PDF: 757HTML: 256 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2676PDF: 846HTML: 5378 -
LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY.
3800PDF: 1150HTML: 2475Figure 1: 227 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
4595PDF: 1525HTML: 8539 -
BACTERIAL INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
3328PDF: 1906HTML: 3698 -
Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts COVID-19 in cancer patients
1273PDF: 817HTML: 256 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2289PDF: 1671HTML: 611 -
HODGKIN LYMPHOMA IN CHILDREN: A 16-YEAR EXPERIENCE AT THE CHILDREN’S WELFARE TEACHING HOSPITAL OF BAGHDAD, IRAQ
1106PDF: 961Suppl. Files: 615HTML: 105 -
The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review COVID-19 in Multiple Myeloma patients
1080PDF: 396HTML: 246 -
QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION
1458PDF: 725HTML: 1386cover letter: 230 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2385PDF: 1367HTML: 17208Bassan Fig.1: 163Bassan Fig.2: 267Bassan Fig.4: 156Fig.3: 228 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
2072PDF: 782HTML: 724Table1: patient's characteristics: 178Table 2: profile of each patient: 201 -







